Cargando...
First Allogeneic CAR T‐Cell Therapy Impresses in Relapsed/Refractory Lymphoma
In the phase I ALPHA trial, the first allogeneic “off‐the‐shelf” CAR T‐cell therapy regimen showed clinical benefits in patients with relapsed/refractory large B‐cell or follicular lymphoma.
Guardado en:
| Publicado en: | Oncologist |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley & Sons, Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7330918/ https://ncbi.nlm.nih.gov/pubmed/32588932 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0570 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|